Chromosomes tell tale of patient's risk for new, future cancer

Chromosomal aberrations analyzed by the researchers could potentially be used as a biomarker to predict a person's risk of developing a second primary tumor, both for Hodgkin's disease patients and for those with other types of cancer, says principal investigator Randa El-Zein, Ph.D., associate professor in M. D. Anderson's Department of Epidemiology.

"Hodgkin's disease is a highly treatable cancer of the lymphatic system and many patients do very well. Yet we know that some patients are at risk of developing another type of cancer later on - solid tumors, leukemia or melanoma, for example - and we cannot identify those patients in advance now," El-Zein says.

"We can use this measure of genetic instability to identify patients at high risk and counsel them to continue regular screening for breast, colon and other cancers even after their Hodgkin's disease has disappeared," El-Zein says. "We also can emphasize that they should especially avoid tobacco use or exposure to environmental toxins at work and eat a healthy diet. You're at risk, don't do anything to make it worse."

The research team looked at 252 adults treated for Hodgkin's disease at M. D. Anderson between 1986 and 1992. The patients had cytogenetic analysis - a close look at the chromosomes in their lymphocytes - done before treatment began and periodically throughout their care.

"We found that people with a higher level of chromosomal aberrations are the ones who developed a second primary tumor," El-Zein notes. The team measured chromosomal breaks per 100 cells and found patients who developed a second primary cancer had 5.91 breaks per 100 cells while those who did not develop a second tumor had 3.97 breaks per 100.

Over a median follow-up period of 13 years, 27 of the patients developed second cancers: five solid tumors, four leukemias, 11 skin cancers and seven lymphomas. Those with higher chromosomal breaks were 2.48 to 2.78 times more likely to develop cancer anew.

Chromosomal breaks occur when both chromosome arms are truncated. Chromatid breaks are those when only one chromosome arm is shortened, yet these appear to be the more predictive type of break, the researchers found.

"Whatever can be applied to Hodgkin's can be applied to other cancers," El-Zein said, so chromosomal screening has potentially broad application for gauging second primary cancer risk across types of cancer. The team is also analyzing chromosomal breaks for correlations to a patient's response to treatment.

El-Zein presented an abstract of the group's research at the AACR annual meeting and her work was highlighted by the research group in a news conference today.

Source: University of Texas M. D. Anderson Cancer Center

You can be replaced: Immune cells compensate for defective DNA repair factor
A new mouse model has provided some surprising insight into XLF, a molecule that helps to repair lethal DNA damage. The research, published by Cell Press in the September 5th issue of the journal Molecular Cell, suggests that although XLF shares many properties with well known DNA repair factors, certain cells of the immune system possess an unexpected compensatory mechanism that that can take over for nonfunctional XLF.
New reasons to avoid grapefruit and other juices when taking certain drugs
Scientists and consumers have known for years that grapefruit juice can increase the absorption of certain drugs — with the potential for turning normal doses into toxic overdoses. Now, the researcher who first identified this interaction is reporting new evidence that grapefruit and other common fruit juices, including orange and apple, can do the opposite effect by substantially decreasing the absorption of other drugs, potentially wiping out their beneficial effects.
Oral cancers linked to genes as well as lifestyle
A major international study published today in Nature Genetics provides the strongest evidence to date that genetics play a role in oral cancers – and further emphasises the part alcohol plays in developing the disease.
Embryonic pathway delivers stem cell traits
Studies of how cancer cells spread have led to a surprising discovery about the creation of cells with adult stem cell characteristics, offering potentially major implications for regenerative medicine and for cancer treatment.
Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
The first study to investigate the effects of chemotherapy on metastatic breast cancer in women with the BRCA1 or BRCA2 gene mutation has shown that standard chemotherapy works better in these patients than in women without the BRCA1/2 mutation.
Nanotech researchers discover cancer cells 'feel' much softer than normal cells
A multidisciplinary team of UCLA scientists were able to differentiate metastatic cancer cells from normal cells in patient samples using leading-edge nanotechnology that measures the softness of the cells.
Balancing act protects vulnerable cells from cancer
When a cell loses some of its weapons to fight cancer, it can still look healthy and act normally — if not forever, at least for a while. In research published in the October 15 issue of Cancer Cell, Rockefeller University scientists show how cells lacking a key receptor in a tumor-suppressing pathway maintain a balance between cell growth and cell death, how they lose this balance and why this loss happens more frequently in some tissues than in others.
MIT works toward novel therapeutic device
MIT and University of Rochester researchers report important advances toward a therapeutic device that has the potential to capture cells as they flow through the blood stream and treat them. Among other applications, such a device could zapp cancer cells spreading to other tissues, or signal stem cells to differentiate.

Chromosomes tell tale of patient's risk for new, future cancer

Related stories:

News discussion: